- Home
- MYN vs YMAB Comparison
MYN vs YMAB Comparison
Compare MYN & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- YMAB
- Stock Information
- Founded
- MYN 1992
- YMAB 2015
- Country
- MYN United States
- YMAB United States
- Employees
- MYN N/A
- YMAB N/A
- Industry
- MYN Finance Companies
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- YMAB Health Care
- Exchange
- MYN Nasdaq
- YMAB Nasdaq
- Market Cap
- MYN 358.2M
- YMAB 386.7M
- IPO Year
- MYN N/A
- YMAB 2018
- Fundamental
- Price
- MYN $9.88
- YMAB $8.59
- Analyst Decision
- MYN
- YMAB Buy
- Analyst Count
- MYN 0
- YMAB 10
- Target Price
- MYN N/A
- YMAB $13.91
- AVG Volume (30 Days)
- MYN 86.0K
- YMAB 889.9K
- Earning Date
- MYN 01-01-0001
- YMAB 11-07-2025
- Dividend Yield
- MYN 4.12%
- YMAB N/A
- EPS Growth
- MYN N/A
- YMAB N/A
- EPS
- MYN N/A
- YMAB N/A
- Revenue
- MYN N/A
- YMAB $85,385,000.00
- Revenue This Year
- MYN N/A
- YMAB N/A
- Revenue Next Year
- MYN N/A
- YMAB $13.97
- P/E Ratio
- MYN N/A
- YMAB N/A
- Revenue Growth
- MYN N/A
- YMAB N/A
- 52 Week Low
- MYN $8.47
- YMAB $3.55
- 52 Week High
- MYN $10.62
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- MYN 79.75
- YMAB 80.77
- Support Level
- MYN $9.20
- YMAB $8.50
- Resistance Level
- MYN $9.33
- YMAB $8.56
- Average True Range (ATR)
- MYN 0.09
- YMAB 0.02
- MACD
- MYN 0.07
- YMAB -0.13
- Stochastic Oscillator
- MYN 95.07
- YMAB 87.50
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.